NEW YORK (GenomeWeb News) – Helicos Biosciences said yesterday that it has for the time being ruled out a potential sale of the company in light of expected revenues through the first quarter of 2010.

In September, Helicos announced that it had hired investment bank Thomas Weisel Partners "to assist the company with its evaluation and execution of strategic alternatives" such as financings, joint ventures, or partnerships.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.